July 1, 2016

One Step Closer to First Human Use of DBS for Stroke Recovery

Cleveland Clinic announces readiness to enroll first patient in trial

650×450-Machado-Surgery

Cleveland Clinic is ready to begin the first human trial of deep brain stimulation (DBS) for post-stroke physical rehabilitation. So announced the trial’s leader, Andre Machado, MD, PhD, Chairman of Cleveland Clinic’s Neurological Institute, this week. The news follows Cleveland Clinic’s recent approval from the FDA to conduct the pioneering trial, as reported earlier this year on Consult QD.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Will promising rodent findings translate?

The go-ahead from the FDA came after 10 years of research by Dr. Machado and his team using a rodent model of stroke. That work showed that stimulation of a novel brain pathway promoted motor recovery along with neurogenesis and angiogenesis in the thalamus and perilesional cortex, as reported last year.

“Our findings suggested that DBS of the cerebello-thalamo-cortical pathway may enhance the brain’s plasticity and ability to form new neural connections during recovery from stroke,” says Dr. Machado, a neurosurgeon (shown in surgery in the photo above) who will perform the DBS procedures in the newly launched trial. “The expectation is that stimulation may augment the effects of physical rehabilitation for stroke.”

He notes that the cerebellum, which controls voluntary muscle movements, was part of the region targeted for stimulation in the hope of reestablishing flow of neurological input to the brain hemisphere affected by stroke.

Advertisement

An adjunct to rehab therapy

Candidates for the new trial will be ischemic stroke patients who suffered a stroke 12 to 24 months previously and have residual severe weakness affecting one arm despite treatment with physical therapy. Key questions the trial will seek to address include:

  • Who are the best candidates for DBS therapy, given the heterogeneity of stroke survivors?
  • At what point in post-stroke recovery would DBS be most beneficial?
  • Is continuous DBS needed, or do benefits endure without ongoing stimulation?

Dr. Machado notes that the goal of DBS in this setting is to augment, not replace, the effects of physical rehabilitation. “The proposition here is to make that recovery greater,” he told Time magazine in a new exclusive interview.

In the same interview he noted what most distinguishes this latest application of DBS from prior uses of the technology, such as for movement disorders: “The big difference is that when we are treating the motor symptoms of Parkinson’s disease, we’re trying to make the symptom, like a tremor, go away. When we are treating stroke, we are really trying to make movement come back. There is something inherently different about that.”

Advertisement

Related Articles

illustration of an alzheimer brain and a packet of sildenafil pills
March 11, 2024
Sildenafil as an Alzheimer’s Candidate Drug: Further Support From Insurance Database and Mechanistic Studies

Real-world claims data and tissue culture studies set the stage for randomized clinical testing

22-NEU-2959102-CQD-Hero-650×450
June 15, 2022
MINDS Study Will Assess Lifestyle Interventions for Slowing Brain Pathology in Preclinical Stages

New grant-funded investigation illustrates impact and reach of Cleveland Clinic Brain Study

22-NEU-2671014-CQD-650×450-Type
March 9, 2022
A Closer Look at the Cleveland Clinic Brain Study

How the new longitudinal investigation could become the Framingham Heart Study of brain health

20-NEU-1959738 powered-exoskeleton-for-gait-training_650x450
October 23, 2020
Study Signals Potential of Powered Exoskeleton for Gait Training in Multiple Sclerosis

Pilot findings show good patient acceptance and safety, early hints of efficacy

20-NEU-1990660-sleep-symptoms-in-health-workers-650×450
October 21, 2020
Electronic Screening for Sleep Disorders Among Healthcare Workers Is Feasible – and Sorely Needed

Study finds high prevalence of symptoms, willingness to seek treatment

20-NEU-1946228 neurofilaments_650x450
September 9, 2020
Serum Neurofilament Light as a Progressive MS Biomarker: Guideposts for the Road Ahead

Panel outlines research priorities around a promising alternative to imaging markers

20-NEU-1951118_Impella-temporary-LVAD_650x450_ (1)
September 4, 2020
Study Finds Clues to Acute Neurologic Events With Short-Term Impella Cardiac Support

Suspected factors include antithrombotic intensity, time on device, presence of thrombocytopenia

20-NEU-1929179 deep-brain-stimulation-for-TBI_650x450
September 3, 2020
Could DBS of the Cerebellar Dentate Nucleus Enhance Post-TBI Rehabilitation?

Preclinical studies will assess whether method developed for stroke recovery curbs deficits after brain injury

Ad